Mexico Neuromodulation for Depression Market Industry Trends and Forecast to 2034: Segmented by (Technology, Setting, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
Mexico · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$21.7 MnPlaceholder estimate
Estimate 2025$23.9 Mn1.5% of the global market
Projected 2034$58.8 Mn 145.6%Adds $34.8 Mn over 9 forecast years
CAGR 2025–203410.5%Faster than 62% of 173 Medical Devices markets here
Key players5
Mexico is 1.52% of the global market.
In Latin America, the largest is Brazil at $35.9 Mn.
4 in MexicoSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Mexico. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The Mexico Neuromodulation for Depression Market Analysis Executive Summary
Neuromodulation for depression uses magnetic or electrical stimulation of the brain, such as TMS, to treat depression that does not respond to medicines.
Key segments of the neuromodulation for Depression market include technology (Transcranial Magnetic Stimulation, Electroconvulsive Therapy and Vagus Nerve Stimulation) and setting (Clinics, Hospitals and Home).
Mexico Neuromodulation for Depression market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
Mexico Neuromodulation for Depression Market Dynamics
Market Growth Drivers
More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the neuromodulation for Depression market. Governments and employers are investing more in mental health care.
Opportunity
Digital tools, new drug classes and care built into primary care and workplaces give the neuromodulation for Depression market strong room to grow worldwide.
Market Restraints
Shortages of mental health professionals, limited insurance coverage, side effects and the need for long-term treatment hold back the neuromodulation for Depression market.
Competitive Landscape for Neuromodulation for Depression Market in Mexico
The neuromodulation for Depression market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Neuromodulation for Depression Market in Mexico
Neuromodulation for Depression in Mexico: rules, payment and research
Medical devices need a sanitary registration from COFEPRIS before sale.[1] Public care comes through IMSS for formal workers, ISSSTE for public employees, and IMSS-Bienestar for people without social security.[2] ClinicalTrials.gov lists 4 studies on Neuromodulation for Depression that are recruiting, active or about to start in Mexico.[3] Suicide rate: 8.8 per 100,000 people in 2023, the latest WHO figure for Mexico.[4]
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how neuromodulation for Depression products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Mexico.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Technology
4.2 By Setting
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Neuronetics
7.2 BrainsWay
7.3 Magstim
7.4 LivaNova
7.5 Flow Neuroscience
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The neuromodulation for Depression market can be segmented based on various criteria, including technology, setting and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Neuromodulation for Depression right now, from free public sources.
Suicide rate: 8.8 per 100,000 people (2023). World: 9.2 per 100,000 people (2023). 2nd highest of the 4 countries we cover in Latin America.[1]
Health spending per person: 761 US$ per person (2023). World: 1,317 US$ per person (2023). 2nd highest of the 4 countries we cover in Latin America.[2]
Doctors: 2.59 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). Highest of the 4 countries we cover in Latin America.[3]
How big is the Neuromodulation for Depression market in Mexico?
Placeholder estimate: about $23.9 Mn in 2025, rising to about $58.8 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Neuromodulation for Depression market in Mexico growing?
Placeholder estimate: about 10.5% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Neuromodulation for Depression market report cover?
The report splits the market by technology (Transcranial Magnetic Stimulation, Electroconvulsive Therapy, Vagus Nerve Stimulation, tDCS), setting (Clinics, Hospitals, Home) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Neuromodulation for Depression market?
Key players include Neuronetics, BrainsWay, Magstim, LivaNova PLC and Flow Neuroscience.
What is driving the Neuromodulation for Depression market?
More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the neuromodulation for Depression market. Governments and employers are investing more in mental health care.
Who regulates Neuromodulation for Depression in Mexico?
Medical devices need a sanitary registration from COFEPRIS before sale. Source: COFEPRIS. Checked 14 Nov 2026.
How is healthcare paid for in Mexico?
Public care comes through IMSS for formal workers, ISSSTE for public employees, and IMSS-Bienestar for people without social security. Source: Mexican Social Security Institute (IMSS). Checked 14 Nov 2026.
How many clinical trials on Neuromodulation for Depression are running in Mexico?
4 studies are recruiting, active or about to start in Mexico, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Mexico. Retrieved 12 Nov 2026.
What does WHO report for Mexico?
Suicide rate: 8.8 per 100,000 people in 2023, the latest WHO figure. Source: WHO Global Health Observatory, Suicide rate (per 100,000 people). Retrieved 15 Nov 2026.
How many people in Mexico are 65 or older?
8.5% of people were 65 or older in 2025. Source: World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 15 Nov 2026.
Mexico 
Brazil
US
China
Canada
Japan
Germany
UK
France
Italy
Spain
India
Ecuador
Saudi Arabia
Australia
New Zealand
Russia
South Africa
UAE
Egypt
Philippines
Hong Kong
Malaysia
Singapore
Thailand
Kenya